Protease-Activated Receptor-2, amide (peptide sequence shortening: SLIGKV-NH2), an activating peptide of PAR2, is a novel, highly potent and selective agonist of protease-activated receptor-2 (PAR2) (Ki = 9.64 μM; IC50 = 10.4 μM).
Physicochemical Properties
| Molecular Formula | C₂₈H₅₄N₈O₇ |
| Molecular Weight | 614.78 |
| Exact Mass | 614.412 |
| CAS # | 190383-13-2 |
| PubChem CID | 10483914 |
| Sequence | Ser-Leu-Ile-Gly-Lys-Val-NH2 |
| Appearance | White to off-white solid powder |
| LogP | 1.779 |
| Hydrogen Bond Donor Count | 9 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 21 |
| Heavy Atom Count | 43 |
| Complexity | 931 |
| Defined Atom Stereocenter Count | 6 |
| SMILES | CC[C@@H]([C@H](NC([C@@H](NC([C@@H](N)CO)=O)CC(C)C)=O)C(NCC(N[C@H](C(N[C@H](C(N)=O)C(C)C)=O)CCCCN)=O)=O)C |
| InChi Key | HOWDUIVVWDUEED-WAUHAFJUSA-N |
| InChi Code | InChI=1S/C28H54N8O7/c1-7-17(6)23(36-27(42)20(12-15(2)3)34-25(40)18(30)14-37)28(43)32-13-21(38)33-19(10-8-9-11-29)26(41)35-22(16(4)5)24(31)39/h15-20,22-23,37H,7-14,29-30H2,1-6H3,(H2,31,39)(H,32,43)(H,33,38)(H,34,40)(H,35,41)(H,36,42)/t17-,18-,19-,20-,22-,23-/m0/s1 |
| Chemical Name | (2S)-6-amino-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]hexanamide |
| Synonyms | Ser-Leu-Ile-Gly-Lys-Val; PAR2 activating peptide; PAR2-AP; PAR-2 (1-6) Human; Protease-Activated Receptor-2, amide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | PAR2 |
| ln Vitro | The peptides that activate PAR2 are SLIGKV-OH, SLIGRL-OH, SLIGKV-NH2, and SLIGRL-NH2. Synthetic agonist peptides that mimic the tethered ligand of PAR2, Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH), Ser-Leu-Ile-Gly-Arg-Leu (SLIGRL-OH), and their amidated forms Ser-Leu-Ile-Gly-Lys-Val-amide (SLIGKV-NH2) Because Ser-Leu-Ile-Gly-Arg-Leu-amide (SLIGRL-NH2) has been shown to be able to activate the receptor without enzymatic cleavage, it has been used as a biological tool to investigate the physiological functions of PAR2. Among the four family subgroups of G-protein-coupled receptors (GPCRs), or PARs, is protease-activated receptor-2, amide. Protease-activated receptors are unique among GPCRs in that they are activated by a proteolytic mechanism. Trypsin, tryptase, and coagulation factors VIIa and Xa are examples of activating proteases for PAR2 that cleave a particular extracellular amino-terminal domain of the receptor to reveal a "tethered ligand," SLIGKV- for human PAR2 and SLIGRL- for mouse/rat PAR2, respectively. This ligand then interacts with the receptor's activation domain to start intracellular signaling pathways[1]. Protease-activated receptor-2 (PAR2) is expressed in a broad range of human tissues and cells and has been linked to the pathophysiology of multiple inflammatory and autoimmune disorders. Proteolysis activates a family of seven transmembrane domain receptor proteins, including PAR2. The process of enzymatic digestion reveals an N-terminus ligand sequence, which binds intramolecularly to the activation site on the extracellular loop II. This triggers nuclear factor-kappa B (NF-κB)-regulated gene transcription and a G-protein-mediated cell-signalling cascade[2]. |
| References |
[1]. Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2. Br J Pharmacol. 2005 May;145(2):255-63. [2]. Protease-activated receptor 2 signalling promotes dendritic cell antigen transport and T-cellactivation in vivo. Immunology. 2010 Jan;129(1):20-7. |
| Additional Infomation | Ser-Leu-Ile-Gly-Lys-Val-Amide is an oligopeptide. |
Solubility Data
| Solubility (In Vitro) | H2O: ~33.3 mg/mL (~54.2 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (162.66 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6266 mL | 8.1330 mL | 16.2660 mL | |
| 5 mM | 0.3253 mL | 1.6266 mL | 3.2532 mL | |
| 10 mM | 0.1627 mL | 0.8133 mL | 1.6266 mL |